Johnson & Johnson: Self-Transformation and Permanence in an Immortal Conglomerate

Johnson & Johnson (hereinafter J&J) is a singularity in modern capitalism that cannot be dismissed as a mere corporate success story. Since its founding in 1886, the company has reigned at the pinnacle of the healthcare industry for over 139 years, embodying the ultimate in "survival of the fittest." While S&P 500 constituents are constantly replaced and former blue-chip companies are forced to exit the market, J&J has maintained its position among the top companies by market capitalization, achieved over 62 consecutive years of dividend increases (Dividend King), and maintained a credit rating (AAA) higher than that of the U.S. government.

This report thoroughly analyzes J&J's history, strategy, financials, and the latest developments as of 2025 to uncover the sources of its "sustainable competitive advantage (Economic Moat)." In particular, following the symbolic spin-off of its consumer health business (Kenvue), the separation plan for its orthopedics business (DePuy Synthes) announced in October 2025 suggests that the company is a practitioner of "self-destructive creation," unafraid of the "conglomerate discount" and constantly concentrating capital in high-profit, high-growth areas (Innovative Medicine and MedTech).

This article details how J&J has transformed its moral compass, "Our Credo," into practical business strategy, prevented the rigidity of a massive organization through decentralized management, and metabolized its portfolio through cold-blooded capital allocation.